Shots: The P-III RELAY study involves assessing the combination of Cyramza + Erlotinib vs PBO + Erlotinib as a 1L treatment in 499 previously untreated patients with mNSCLC with EGFR […]readmore
Tags : (ramucirumab)
Shots: The approval is based on REACH‑2 study (NCT02435433) results assessing Cyramza (ramucirumab) + BSC vs PBO + BSC in 292 advanced HCC patients in the ratio (2:1) with alpha-fetoprotein […]readmore
Shots: The P-III RELAY study involves assessing of Cyramza + erlotinib vs PBO + erlotinib in 449 patients with EGFR mutated mNSCLC across North America, EU, and Asia The P-III […]readmore